General

SpaceX (NASDAQ:SPCX) said Monday it will primarily release its corporate updates to the public through its website and social media account on X, rather than traditional wire services, further deepening Elon Musk‘s push to make the social media platform a central hub for corporate...

Vice President JD Vance said Monday that Iran could gain access to a $300 billion reconstruction fund under a peace agreement with the United States if Tehran meets its obligations. Vance Says Fund Depends On Iran Compliance Asked by CBS News' Ed O'Keefe about the fund, Vance said, "Well, Ed, that'...

I talked about Defi inflated yields last month. Investors often mistake a large number for a good investment. This error drives the current crypto mania. You see a yield of 19.0% on Cosmos staking and assume you have found a financial loophole. You ignore the source of that money. Traditional...

Space Exploration Technologies Corp. (NASDAQ:SPCX) went public last Friday and it set new records for retail investor demand in a single session. SPCX stock is moving. See the chart and price action here. Leif Abraham, co-CEO of financial platform Public, told CNBC on Monday that SpaceX’s...

Eli Lilly and Co. (NYSE:LLY) said Sunday that its Phase 3 BRUIN CLL-322 trial met its primary endpoint, with the addition of Jaypirca (pirtobrutinib) to venetoclax and rituximab significantly improving progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia or...

The U.S. Food and Drug Administration has granted accelerated approval to Sanofi SA’s (NASDAQ:SNY) Tzield (teplizumab-mzwv) to delay the decline of endogenous insulin production in children ages 8 to 17 who have been recently diagnosed with stage 3 type 1 diabetes (T1D). The decision expands...

The U.S. Food and Drug Administration (FDA) on Friday cleared Dexcom Inc.‘s (NASDAQ:DXCM) Stelo Glucose Biosensor System for over-the-counter use in children ages 2 and older who do not use insulin, expanding access to continuous glucose monitoring for younger patients. The FDA previously...

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) stock is trading higher on Monday after the company reported preliminary results from an ongoing Phase 2 study evaluating setmelanotide in patients with Prader-Willi syndrome (PWS). The six-month data shared on Saturday showed improvements in body mass...

AstraZeneca Plc (NYSE:AZN) received two significant regulatory updates from the U.S. Food and Drug Administration, with its cancer therapy Truqap gaining approval for a subset of prostate cancer patients and its kidney disease treatment Ultomiris receiving Priority Review for a new indication....

Neumora Therapeutics Inc. (NASDAQ:NMRA) on Monday said it is discontinuing development of its lead depression candidate, navacaprant, after two Phase 3 studies failed to achieve statistical significance on both primary and key secondary endpoints in patients with major depressive disorder (MDD)....

Elicio Therapeutics Inc. (NASDAQ:ELTX) stock is trading lower on Monday after disappointing results from its Phase 2 AMPLIFY-7P study of ELI-002 7P in patients with mutant KRAS-driven pancreatic ductal adenocarcinoma (PDAC) following standard locoregional treatment. Elicio Therapeutics Misses...

Roku Inc. (NASDAQ:ROKU) shares surged Friday after a report suggested the streaming platform is exploring a potential sale. Now, JPMorgan believes one name stands out from a crowded field of possible buyers. In a note following the report, analyst Cory Carpenter said Roku’s combination of TV...

Lexeo Therapeutics Inc. (NASDAQ:LXEO) stock rose Monday as the company announced a regulatory update regarding its pivotal SUNRISE-FA 2 trial for gene therapy candidate LX2006. LXEO Stock Jumps The gene therapy company finalized the protocol for its SUNRISE-FA 2 pivotal trial, which aims to...

Space stocks got a vote of confidence Sunday as KeyBanc Capital Markets upgraded both Rocket Lab Corp. (NASDAQ:RKLB) and Firefly Aerospace (NASDAQ:FLY) to Overweight, calling the post-SpaceX IPO selloff a buying opportunity rather than a signal of structural weakness. RKLB stock is moving. See the...

Traws Pharma Inc. (NASDAQ:TRAW) shares are trading lower on Monday as the company faces regulatory challenges regarding its influenza treatment program. The decline follows a recent update indicating that the planned Phase 2a human influenza challenge study for its lead compound, tivoxavir marboxil...